Clephedrone

Uncontrolled hypertension, Recent myocardial infarction, Decompensated heart failure, Known cardiac arrhythmias, Long QT syndrome

Clephedrone produces dose-dependent blood pressure and heart rate elevation comparable to mephedrone in telemetry-implanted rats. Computational modeling predicts hERG channel inhibition, suggesting potential for QT interval prolongation. Individuals with pre-existing cardiovascular disease face compounded risk from both the sympathomimetic burden and potential arrhythmogenicity.

Epilepsy, History of seizures, Conditions that lower seizure threshold

Monoamine releasers as a class lower seizure threshold. Clephedrone's robust NET and DAT substrate activity predicts this effect. No substance-specific seizure data exist, but the mechanism is well-established for the stimulant class.

Bipolar disorder, Schizoaffective disorder, Schizophrenia, History of psychotic episodes

Clephedrone's robust dopamine and norepinephrine releasing activity may precipitate manic or psychotic episodes in vulnerable individuals. This is a well-established class-level risk for dopaminergic stimulants and monoamine releasers. No substance-specific psychiatric safety data exist.

Liver disease, Cirrhosis, Impaired hepatic function, Concurrent use of CYP inhibitors

Clephedrone is formally classified as a low-clearance compound based on human hepatocyte incubation (Lopes 2023), distinguishing it from most other synthetic cathinones. Reduced hepatic function would further slow elimination, increasing risk of toxic accumulation — particularly with repeated dosing. CYP enzyme involvement is unknown, adding further unpredictability.

Pregnancy, Breastfeeding, Planned conception

No reproductive toxicity data exist for clephedrone. Monoamine releasing agents are contraindicated during pregnancy as a class due to presumed teratogenicity from disruption of fetal monoaminergic signaling and cardiovascular effects (sympathomimetic burden). Excretion in breast milk is unknown.

Concurrent use of monoamine oxidase inhibitors including phenelzine, tranylcypromine, selegiline (at antidepressant doses), moclobemide, isocarboxazid

Concurrent use of clephedrone with any monoamine oxidase inhibitor carries severe risk of fatal serotonin syndrome and hypertensive crisis. Clephedrone is a non-selective monoamine releasing agent (DAT/NET/SERT substrate); MAOIs prevent the enzymatic breakdown of released monoamines, producing dangerous accumulation. This is a well-established class-level contraindication for all monoamine releasing agents.

Concurrent SSRI use, Concurrent SNRI use

Serotonin reuptake inhibitors compete with clephedrone at SERT and increase baseline serotonergic tone, creating unpredictable pharmacodynamic interactions. Sertraline co-administration with 4-CMC was documented in a fatal polydrug case (Nowak 2021). Risk of serotonin syndrome increases with dose.